Literature DB >> 12890863

The effect of transforming growth factor beta1 gene polymorphisms in ankylosing spondylitis.

E Jaakkola1, A M Crane, K Laiho, I Herzberg, A-M Sims, L Bradbury, A Calin, S Brophy, M Kauppi, K Kaarela, B P Wordsworth, J Tuomilehto, M A Brown.   

Abstract

OBJECTIVES: To determine whether genetic polymorphisms in or near the transforming growth factor beta1 (TGFB1) locus were associated with susceptibility to or severity of ankylosing spondylitis (AS).
METHODS: Five intragenic single-nucleotide polymorphisms (SNP) and three microsatellite markers flanking the TGFB1 locus were genotyped. Seven hundred and sixty-two individuals from 184 multiplex families were genotyped for the microsatellite markers and two of the promoter SNPs. One thousand and two individuals from 212 English and 170 Finnish families with AS were genotyped for all five intragenic SNPs. A structured questionnaire was used to assess the age of symptom onset, disease duration and disease severity scores, including the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and BASFI (Bath Ankylosing Spondylitis Functional Index).
RESULTS: A weak association was noted between the rare TGFB1 +1632 T allele and AS in the Finnish population (P = 0.04) and in the combined data set (P = 0.03). No association was noted between any other SNPs or SNP haplotype and AS, even among those families with positive non-parametric linkage scores. The TGFB1 +1632 polymorphism was also associated with a younger age of symptom onset (English population, allele 2 associated with age of onset greater by 4.2 yr, P = 0.05; combined data set, allele 2 associated with age of onset greater by 3.2 yr, P = 0.02). A haplotype of coding region SNPs (TGFB1 +869/+915+1632 alleles 2/1/2) was associated with age of symptom onset in both the English parent-case trios and the combined data set (English data set, haplotype 2/1/2 associated with age of onset greater by 4.9 yr, P = 0.03; combined data set, haplotype 2/1/2 associated with greater age of onset by 4.2 yr, P = 0.006). Weak linkage with AS susceptibility was noted and the peak LOD score was 1.3 at distance 2 cM centromeric to the TGFB1 gene. No other linkage or association was found between quantitative traits and the markers.
CONCLUSION: This study suggests that the polymorphisms within the TGFB1 gene play at most a small role in AS and that other genes encoded on chromosome 19 are involved in susceptibility to the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12890863     DOI: 10.1093/rheumatology/keg457

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  8 in total

1.  Susceptibility to ankylosing spondylitis: evidence for the role of ERAP1, TGFb1 and TLR9 gene polymorphisms.

Authors:  Wenliang Wu; Yan Ding; Yunzhen Chen; Zhao Hua; Haichun Liu; Hongliang Wang; Guangjun Jiao
Journal:  Rheumatol Int       Date:  2011-07-16       Impact factor: 2.631

Review 2.  The Genetic Basis of Peyronie Disease: A Review.

Authors:  Amin S Herati; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2016-01-08

3.  Ankylosing spondylitis susceptibility loci defined by genome-search meta-analysis.

Authors:  Young Ho Lee; Young Hee Rho; Seong Jae Choi; Jong Dae Ji; Gwan Gyu Song
Journal:  J Hum Genet       Date:  2005-09-21       Impact factor: 3.172

4.  Tgfbr2 regulates the maintenance of boundaries in the axial skeleton.

Authors:  Michael O Baffi; Molly A Moran; Rosa Serra
Journal:  Dev Biol       Date:  2006-06-07       Impact factor: 3.582

5.  Susceptibility to ankylosing spondylitis: no evidence for the involvement of transforming growth factor beta 1 (TGFB1) gene polymorphisms.

Authors:  M van der Paardt; J B A Crusius; M A García-González; B A C Dijkmans; A S Peña; I E van der Horst-Bruinsma
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

6.  Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases.

Authors:  R J François; L Neure; J Sieper; J Braun
Journal:  Ann Rheum Dis       Date:  2005-10-25       Impact factor: 19.103

7.  Molecular profiling of the developing mouse axial skeleton: a role for Tgfbr2 in the development of the intervertebral disc.

Authors:  Philip Sohn; Megan Cox; Dongquan Chen; Rosa Serra
Journal:  BMC Dev Biol       Date:  2010-03-09       Impact factor: 1.978

8.  Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.

Authors:  S Visvanathan; C Wagner; J C Marini; D Baker; T Gathany; J Han; D van der Heijde; J Braun
Journal:  Ann Rheum Dis       Date:  2007-07-20       Impact factor: 19.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.